TASLY(SH:600535) Zheng Quan Zhi Xing·2025-08-15 11:17Core Viewpoint - The Supervisory Board of Tianjin Tasly Pharmaceutical Group Co., Ltd. has approved the 2025 semi-annual report and profit distribution plan, confirming compliance with legal and regulatory requirements [1][2]. Group 1: Meeting Details - The 8th meeting of the 9th Supervisory Board was held on August 14, 2025, with all 5 supervisors present [1]. - The meeting was conducted in accordance with the Company Law and the Articles of Association [1]. Group 2: Semi-Annual Report Approval - The Supervisory Board reviewed the 2025 semi-annual report and found that the preparation and review processes complied with all relevant laws, regulations, and internal management systems [1]. - The content and format of the report meet the requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange, accurately reflecting the company's operational and financial status for the first half of 2025 [1]. Group 3: Profit Distribution Plan - The profit distribution plan for the first half of 2025 was approved, taking into account internal and external factors, the company's operational status, future development plans, funding needs, and stakeholder expectations [2]. - The voting results for the profit distribution plan showed 5 votes in favor, with no opposition or abstentions [2].